Abstract 1587P
Background
The treatment and survival associated with multiple cancers has dramatically improved over the past decade with therapeutic advances. While print and broadcast media often report on cancer, it is unknown how movies depict cancer, treatment, or outcomes. Given that film may influence and shape public opinion, and potential willingness to seek out cancer treatment, we evaluated the portrayal of cancer in movies.
Methods
We searched for movies released between 2010 and 2020 using IMDb.com with search references for cancer in keywords. We excluded non-English language movies to avoid error in translation. We viewed and coded movies to include character’s role, diagnosis, curability, treatment, race/ethnicity, and gender. Per institutional policies, the study was not submitted for IRB approval because all data are publicly available.
Results
We identified 104 movies depicting cancer and oncologists between 2010 and 2020. A total of 108 characters with cancer were portrayed. Female characters were depicted more often (n = 60, 55.6%) than male characters (n = 48, 44.4%). The type of cancer was most often not specified in the movie (n = 40, 37%). The majority of characters were portrayed as having an incurable cancer (n = 70, 64.8%), while the curability of cancer was unknown in 21.3% of roles (n = 23). Only 13.9% of characters (n = 15) were depicted as having a curable cancer. The cancer-directed therapy was not specified or depicted for most characters (n = 37, 34.3%). When treatment was depicted or specified, chemotherapy was the most common treatment shown (n = 36, 33.3%). Two characters were depicted as choosing alternative medicine. Twelve characters were shown to choose forgoing cancer directed treatment. Zero characters (0%) were shown receiving immune checkpoint inhibitors or genomic-based therapies. Hospice or palliative care was discussed and offered for 8 characters (7.4%).
Conclusions
Most movies released from 2010 to 2020 with an oncology storyline do not contain granular details about cancer type or treatment. Most characters were portrayed as having an incurable malignancy. Chemotherapy was the most commonly depicted therapy while newer therapies were not depicted. The portrayal of oncology in recent English-language movies does not accurately reflect the reality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.J. Benjamin: Financial Interests, Advisory Board: Astellas, Eisai, Seagen; Financial Interests, Speaker’s Bureau: Merck; Financial Interests, Other: Merck. A. Rezazadeh Kalebasty: Financial Interests, Personal, Advisory Board, advisory board and speaker: Exelixis, Bayer, Pfizer, Genentech, EMD Serono; Financial Interests, Personal, Advisory Board, speaker and advisory board: AstraZeneca, Novartis, BMS; Financial Interests, Personal, Invited Speaker: Janssen, Astellas Medivation, Pfizer, Novartis, Genentech/Roche, Eisai, AstraZeneca, BMS, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/ Astellas, Myovant, Gilead Sciences; Financial Interests, Personal, Advisory Board: Gilead Sciences; Financial Interests, Institutional, Local PI: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, BMS, Eisai, Macrogenics, Astellas, Beyond Spring, Bioclin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizy, Arnivas, Navire, Point biopharma, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10